Medscape1y
Efficacy and Safety of Widely Used Treatments for Macular Oedema Secondary to Retinal Vein Occlusion
Background Macular oedema secondary to retinal vein occlusion (RVO) can cause vision loss due to blockage of the central retinal vein (CRVO) or a branch retinal vein (BRVO). This systematic review ...
Medscape10d
Treatment of Branch Retinal Vein Occlusion Induced Macular Edema With Bevacizumab
We show that intravitreal Bevacizumab treatment for macular edema induced by BRVO leads to a fast and significant improvement of visual acuity and a concurrent decrease of CRT. Similar results ...
Business Wire17d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Outside the United States, Lucentis is approved in more than 120 countries to treat adult patients with wet AMD, and for the treatment of visual impairment due to DME, due to macular edema secondary ...
pharmaphorum10y
Bayer submits Eylea for use in BRVO
Bayer has submitted Eylea for European approval for use in macular oedema following branch retinal vein occlusion (BRVO). The injectable biologic is competing with Novartis' rival Lucentis in the ...